ArticleTranslational oncology2026
In vivo and FACS-based CRISPR/Cas9 screening uncovers VENTX as a crucial element in maintaining seminoma stemness.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Seminoma, which is the most frequent testicular germ cell tumor, has stem cell-like features related to treatment resistance and recurrence, yet the molecular mechanisms that preserve its stemness are not well understood. This study aimed to discover the tumorigenesis and stemness regulation of seminoma. In vivo CRISPR/Cas9 knockout library screening was performed using Tcam-2 seminoma cells implanted into NSG mice to identify tumorigenesis drivers. Parallel FACS-based screening enriched CD117/CD133 double-negative cells to assess the regulators of seminoma stemness. Functional validation included clonogenicity assays, sphere formation tests, and tumor initiation experiments in vivo. RNA sequencing analyzed downstream pathways. In vivo and FACS-based CRISPR/Cas9 screening uncovers VENTX as a crucial element in maintaining seminoma stemness. Functional validation showed that VENTX knockout decreased clonogenicity, sphere formation, and CD117+/CD133+ populations in Tcam-2 cells, and also hindered tumor initiation in vivo. RNA sequencing identified a connection between VENTX and pluripotency pathways, demonstrating a downregulation of ID1/2/3 (essential differentiation inhibitors) and an imbalance in Wnt/β-catenin and TGF-β signaling. VENTX expression showed a significant association with DNA methylation-based stemness scores in testicular germ cell tumors. In conclusion, VENTX is a key regulator of seminoma stemness, presenting a promising target for therapy to address recurrence and resistance in seminoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.